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Abstract
Objective—Evidence suggests that short and long sleep are associated with a higher risk of type 
2 diabetes. Using successive data waves spanning more than 20 years we examined whether a 
change in sleep duration is associated with incident diabetes.
Research Design and Methods—Sleep duration was reported at the beginning and end of 
four 5-year cycles: 1985-88 to 1991-94 (N=5613); 1991-94 to 1997-99 (N=4193); 1997-99 to 
2002-04 (N=3840); 2002-04 to 2007-09 (N=4195). At each cycle, change in sleep duration was 
calculated for participants without diabetes. Incident diabetes at the end of the subsequent 5-year 
period was defined using: (1) fasting glucose; (2) 75g oral glucose tolerance test; and (3) glycated 
hemoglobin, in conjunction with diabetes medication and self-reported doctor diagnosis.
Results—Compared to the reference group of persistent 7-hour sleepers, an increase of ≥2hours 
sleep per night was associated with a higher risk of incident diabetes; Odds Ratios (95% 
Confidence Intervals) 1.65 (95% CI: 1.15, 2.37), in analyses adjusted for age, sex, employment 
grade and ethnic group. This association was partially attenuated by adjustment for body mass 
index and change in weight; 1.50 (1.04, 2.16). An increased risk of incident diabetes was also seen 
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in persistent short sleepers (average ≤5.5 hours/night); 1.35 (1.04, 1.76), but this evidence 
weakened on adjustment for body mass index and change in weight; 1.25 (0.96, 1.63).
Conclusion—This study suggests that individuals whose sleep duration increases are at an 
increased risk of type 2 diabetes. Greater weight and weight gain in this group partly explain the 
association.
Recent meta-analyses of prospective studies have provided evidence of a U-shaped 
association between sleep duration and a higher incidence of type 2 diabetes, with both short 
and long sleep duration associated with greater risk (1-3). The association between short 
sleep and diabetes is biologically credible (4). Laboratory studies have shown sleep 
restriction and poor sleep quality to be linked to glucose dysregulation, with increases in 
hunger and appetite via down-regulation of satiety and up-regulation of appetite-stimulating 
hormones (5), indicating pathways to diabetes via adiposity and insulin resistance (6). In 
contrast, the association observed between long sleep and adverse health outcomes has 
mostly been attributed to reverse causation from subclinical or undetected morbidity (7).
Increasing concerns about reductions in night time sleep duration due to the 24/7 society (1) 
cannot be addressed by studies based on a one-off measurement of sleep duration, a 
limitation that pertains to almost all observational studies to date (1,2). From such studies it 
is impossible to determine whether associations observed between short or long sleep and 
diabetes are generated by persistent exposure, or whether decreases or increases from a more 
normal average of 7-hours per night also confer risk. A decrease or increase in sleep 
duration from normal to short or long sleep has been associated with increased all-cause 
mortality (8), but we are not aware of any population level investigations of change in sleep 
duration and incidence of type 2 diabetes.
In this paper, we examined potential longitudinal associations between changes in sleep 
duration over 5-year exposure periods and incident type 2 diabetes in the subsequent 5-year 
period. Using a large, prospective study of middle-aged women and men, we took account 
of changes in adiposity, a potential confounder and mediator of these associations (7).
RESEARCH DESIGN AND METHODS
Study population
The target population for the Whitehall II study was all London-based office staff aged 
35-55 in 20 civil service departments in 1985. Of these, 10 308 enrolled, a response 
proportion of 73% (9). Data collection at enrolment, 1985-88, and in 1991-94, 1997-99, 
2002-04, 2007-09 and 2012-13 involved a clinical examination and self-administered 
questionnaire. Additional limited data collections via self-administered questionnaire only 
were conducted in 1989, 1995, 2001 and 2006. The current study takes advantage of these 
data to examine associations between changes in sleep duration and incident type 2 diabetes 
over four successive data cycles (10). One data cycle includes three phases of data; change 
in sleep duration over a 5-year exposure period, e.g. 1985-88 to 1991-94, and incident 
diabetes over the subsequent 5-year period, 1991-94 to 1997-99 – Appendix Table 1.
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Assessment of exposure
Sleep duration was measured using the question ‘How many hours of sleep do you have on 
an average week night?’ Response categories were ≤5, 6, 7, 8, and ≥9. Sleep duration in 
1985-88, 1991-94, 1997-99, 2002-04 and 2007-09 was used to determine change in sleep 
duration over four exposure periods: 1985-88 to 1991-94; 1991-94 to 1997-99; 1997-99 to 
2002-04; and 2002-04 to 2007-09. To calculate change, baseline sleep duration was 
subtracted from sleep duration at follow-up. As sleep duration was measured only in whole 
numbers of hours, durations of sleep that differed by 0 or 1 hour between successive phases 
were considered not to be different and classified as ‘no change in sleep duration’. For these 
‘stable’ sleepers, average sleep duration was calculated and categorized into five levels: 
≤5.5, 6.0-6.5, 7.0, 7.5-8.0 and ≥8.5 hours. Decreased sleep was defined as a decrease of ≥2 
hours and increased sleep as an increase of ≥2 hours in sleep over the 5-year sleep exposure 
period.
Ascertainment of incident type 2 diabetes
At the end of the 5-year sleep exposure period for each data cycle (which coincided with the 
start of the 5-year incident diabetes outcome period for that cycle) participants reporting use 
of diabetes medication or diabetes diagnosed by a doctor (doctor-diagnosed), or identified 
via the Whitehall II clinical examination were classified as prevalent diabetes cases and 
removed from analyses of the outcome for that data cycle. The clinical examination included 
a 75g oral glucose tolerance test (OGTT) with determination of fasting and 2-hour postload 
glucose (venous blood after ≥5-hour fast). Samples were drawn into fluoride monovette 
tubes and centrifuged on site within one hour. Blood glucose was measured using the 
glucose oxidase method, as previously described (11). In addition to the fasting glucose 
sample, glycated hemoglobin (HbA1c) was measured in EDTA whole blood using a 
calibrated high-performance liquid chromatography system with automated hemolysis 
before injection.
Incident type 2 diabetes at the end of each outcome period was defined as follows: either (i) 
fasting glucose ≥7·0 mmol/L or participant report of doctor-diagnosed diabetes (data cycles 
1-4); (ii) or OGTT criteria (12), fasting glucose ≥7·0 mmol/L, or 2 hour post-load glucose 
≥11·1 mmol/L or participant report of doctor-diagnosed diabetes (data cycles 1-3); or (iii) 
HbA1c ≥6.5% (48 mmol/mol) or participant report of doctor-diagnosed diabetes (data cycles 
3 and 4) (13). For three of the incident diabetes outcome periods; 1991-94 to 1997-99, 
1997-99 to 2002-04, and 2002-04 to 2007-09, questionnaire only data were also available 
midway between the main data collection points, in 1995, 2001 and 2006 respectively. 
Participants identified as incident cases of diabetes by self-reported doctor-diagnosis in these 
questionnaires were included among the incident cases for that 5-year outcome period. Since 
the definition of incident diabetes changed across the data cycles, we created an all-inclusive 
definition which used all glycemic data available at each data cycle. This all-inclusive 
definition of incident diabetes used OGTT criteria or participant report of doctor diagnosis 
for data cycles 1 and 2, OGTT or HbA1c criteria or participant report of doctor diagnosis for 
data cycle 3 and fasting glucose or HbA1c criteria or participant report of doctor diagnosis 
for data cycle 4.
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Assessment of covariates
At each data cycle covariates included age and sex from the beginning of the outcome 
period, body mass index (BMI) in kg/m2 at the beginning of each exposure and outcome 
period (1991-94, 1997-99, 2002-04, 2007-09, 2012-13), socioeconomic position measured 
as employment grade (low, intermediate, high) and ethnicity (white, south Asian, Black). All 
measures were obtained as described previously (9).
Statistical analysis
The data from each cycle were combined to form a single dataset of person-observations. 
Conditional logistic regression models, stratified by data cycle, with incident diabetes as the 
outcome, were fitted to estimate odds ratios at each data cycle: (i) for stable sleepers with 
averages of ≤5.5, 6.0-6.5, 7.5-8.0 and ≥8.5 hours sleep per night and (ii) those whose sleep 
duration decreased or increased by ≥2 hours. Those who slept 7 hours per night on both 
occasions were used as the reference group in both cases. These odds ratios were estimated 
using a single unified model. Of the 6449 participants who contributed to these analyses, 
24%, 21%, 11% and 44% contributed data from 1, 2, 3 and 4 cycles of data, respectively. 
The non-linear effect of average sleep on incident diabetes in stable sleepers was tested by 
fitting linear and quadratic terms for average sleep in these participants. All models were 
initially adjusted for age and sex at the beginning of the outcome period. Further 
adjustments were made for ethnicity and employment grade. Lastly the analyses were 
adjusted for BMI at the beginning of each exposure and outcome period using two separate 
terms. Missing data on covariates were present in 9% of the person observations. These 
observations were excluded from all analyses so that the increasing degrees of adjustment 
for covariates were conducted on the same dataset. All analyses were conducted using SAS 
version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Appendix Table 1 presents the numbers of participants that contributed to the analyses of 
average sleep duration and change in sleep duration across the four data cycles. The analyses 
of diabetes defined using a fasting glucose of ≥7.0 mmol/L included 17 841 person-
observations for normoglycemic participants at baseline, among whom 574 were diagnosed 
as incident diabetes cases during follow-up. Of these cases, 280 had a fasting glucose of 
≥7.0 mmol/L, while the remaining 294 reported doctor-diagnosed diabetes. For type 2 
diabetes based on the OGTT criteria there were 13 435 person-observations and 587 incident 
diabetes cases, of whom, 133 had a fasting glucose of ≥7.0 mmol/L, 221 had a 2 hour post-
load glucose ≥11·1 mmol/L, 60 had both measures elevated, and 173 reported doctor-
diagnosed diabetes. For type 2 diabetes defined according to the level of glycated 
hemoglobin, there were 8 181 person-observations and 401 diabetes cases, of whom, 269 
had HbA1c ≥6.5% (48 mmol/mol) and the remaining 132 reported doctor-diagnosed 
diabetes. The all-inclusive definition of incident diabetes using all glycemic data available at 
each cycle was used in the main analyses. These analyses included 17 778 person-
observations and 816 diabetes cases.
Ferrie et al. Page 4
Diabetes Care. Author manuscript; available in PMC 2015 August 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Characteristics of the participants included in the incident diabetes analyses for each data 
cycle are presented in Table 1. An expected pattern of age-related changes were seen; sleep 
duration tended to decrease and BMI increase over time.
Findings for the association between sleep duration and diabetes defined using all incident 
cases are presented in Table 2. There is evidence of a non-linear (reverse J-shaped) 
association between average sleep duration and incident diabetes in participants whose sleep 
duration did not change over the sleep exposure period for each data cycle. The strong 
association observed between persistent short sleep and incident diabetes in the age and sex-
adjusted analyses, Odds Ratio (95% Confidence Interval) 1.59 (95% CI 1.22-2.05), was 
somewhat attenuated by adjustment for ethnic group and employment grade, 1.35 
(1.04-1.76). Further adjustment for BMI at the beginning and end of the exposure and 
outcome period partly explained this association, 1.25 (0.96, 1.63).
Compared to a constant duration of 7 hours sleep at the beginning and end of the exposure 
period, there was strong evidence of an association between an increase in sleep duration ≥2 
hours and incident diabetes in the age and sex adjusted analyses, 1.83 (1.28, 2.60) – Table 3. 
These associations were slightly attenuated on further adjustment for ethnic group and 
employment grade, 1.65 (1.15, 2.37). Although further adjustment for BMI at the beginning 
and end of the exposure and outcome period partly explained this association, 1.50 (1.04, 
2.16) an independent association between an increase in sleep duration and incident diabetes 
remained.
Sensitivity analysis
The analyses presented in Tables 2 and 3 use the most inclusive definition of diabetes at 
each data cycle. Depending on the cycle, this includes diabetes self-reported as doctor 
diagnosed and/or diagnosed by fasting glucose (all four data cycles), and/or by 2-hour post-
load glucose (first 3 data cycles), and/or by HbA1c (last two data cycles). As these different 
diagnostic criteria lead slightly different groups of participants to be diagnosed with 
diabetes, our findings are presented separately by diagnostic criteria in Appendix Tables 2-4. 
Overall the findings from these sensitivity analyses are remarkably consistent across the 
definitions most commonly used for the diagnosis of diabetes. They also provide some 
evidence to support an association between a decrease in sleep and incident diabetes in the 
age and sex-adjusted analyses, but this is attenuated on further adjustment. Further analyses, 
which compare the age and sex adjusted odds ratios presented in Tables 2 and 3 and 
Appendix Tables 2-4 with those obtained from including the observations with missing 
covariate data, showed the two sets of analyses to be close with similar patterns observed 
between sleep duration and change in sleep duration and incident diabetes – Appendix Table 
5.
DISCUSSION
Our findings among stable sleepers suggest a non-linear (reverse J-shaped) association 
between sleep duration and incident diabetes. This is reassuring as it partly replicates 
previous findings and provides some external validity of our data (1,2). We also found that 
persistent short sleep and an increase of two hours or more in sleep duration over a five-year 
Ferrie et al. Page 5
Diabetes Care. Author manuscript; available in PMC 2015 August 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
exposure period, compared to a constant 7 hours per night, were associated with an 
increased risk of developing type 2 diabetes in analyses adjusted for age, sex, ethnic group 
and employment grade. A set of sensitivity analyses showed these findings to be remarkably 
consistent across the definitions most commonly used for the diagnosis of diabetes; fasting 
glucose, OGTT and HbA1c. Further adjustment for body mass index and change in weight 
weakened the association between persistent short sleep and diabetes. Although similar 
adjustment explained part of the association between an increase in sleep and incident 
diabetes, a strong independent association remained.
It is an interesting and new observation that persistent short sleep is more deleterious than a 
decrease in sleep duration over a 5-year period. This may be related to the longer exposure 
to short sleep among persistent short sleepers, or because decreases in sleep duration are 
common with increasing age and may lead to age-specific “normal” values of sleep 
duration. There are a number of potential mechanisms through which short sleep may affect 
glucose metabolism (4). One is via alterations in the neurohormonal regulation of eating 
habits. Laboratory studies have shown sleep restriction to be associated with increased 
appetite, especially for calorie dense foods, via down-regulation of satiety and up-regulation 
of appetite-stimulating hormones (5). Were the resulting hunger to translate into additional 
calorie intake, weight gain, which is associated with the development of diabetes, would be 
expected to occur over time. Given this potential association between sleep duration and 
increases in adiposity, it is unsurprising that adjustment for this important risk factor for type 
2 diabetes attenuated the association observed between persistent short sleep and incident 
diabetes.
Activation of inflammatory pathways may also play a role in the association between 
persistent short sleep and diabetes, as there is a well-established association between 
inflammation and incident type 2 diabetes (15). Experiments suggest that prolonged sleep 
deprivation in rats is associated with an evolving pro-inflammatory state (16), and common 
forms of sleep loss, such as reductions of 25%-50% across consecutive nights, appear to 
induce an increase in levels of interleukin-6 and C-reactive protein (17:18). Another 
potential mechanism is through melatonin, which is regulated by the circadian clock and is 
inhibited by light to the retina. Melatonin and its receptors, which are widely expressed, are 
associated with metabolic pathways (20). Melatonin is reduced in short sleepers and recent 
work has shown lower levels of melatonin secretion to be independently associated with a 
higher risk of developing type 2 diabetes (21).
Contrary to expectations and at seemingly odds with our findings for persistent short sleep, 
we did not find any consistent association between a decrease in sleep and incident diabetes 
in these analyses, possibly due to the relatively small number of participants and events in 
this category.
As the current study appears to be the first to demonstrate an association between increased 
sleep and incident diabetes, potential mechanisms are based on those underlying the 
association between long sleep duration and increased diabetes. In addition to an association 
with obesity, long sleep has been shown to be associated with other risk factors for diabetes, 
such as depression, low socioeconomic status, poor physical health, and low physical 
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activity (22:23). Long sleep could also be a marker of associated sleep disorders. 
Obstructive sleep apnea, for example, is a cause of increased need for sleep and moderate to 
severe apnea is also associated with an increased risk of type 2 diabetes (24). Similarly, 
reports of long sleep may be a proxy for time in bed to compensate for poor quality sleep, 
which in turn has been shown to be associated with poor glucose regulation (25:26). Long 
sleep can also be an epiphenomenon of comorbidity or the result of prodromal disease, 
including pre-diabetes, which may result in tiredness. Finally, both short and long sleepers 
may be characterized by a distinctive phenotype (22), or even genotype that may confound 
observed associations (27).
Future work in this field should address the following limitations of this study: First, our 
sleep measure was self-reported, with sleep duration categories that ranged only from ≤ 5 
hours per night to ≥9 hours per night. In our analyses we treated these groups as if they were 
5 hours and 9 hours exactly. At the short sleep end of the sleep duration distribution this 
may have resulted in some misclassification of participants who move from 6 hours to ≤5 
hours, or vice versa. They are currently allocated to the no change, short sleep group, 
although some of them might have decreased or increased sleep. As our analyses show that 
those with decreased sleep tend to have a lower risk of diabetes than the group of stable 
short sleepers and those with increased sleep a higher risk, such potential misclassification 
would have little effect on the estimates for stable short sleepers, although it may result in 
slightly fewer participants in the change in sleep groups. A similar misclassification might 
have occurred at the long sleep end of the distribution (the stable long sleep group) with the 
result that this group contains some participants whose sleep duration did change and who 
are at higher risk of diabetes. The odds ratio in the stable long sleep group may, therefore, be 
slightly overestimated. Self-reported sleep duration is strongly associated with objectively 
ascertained health outcomes (8:28), and assessments in the primary healthcare setting rely 
on self-reports from patients. In addition, small-scale investigations have shown moderately 
good correlations between subjective estimates and sleep diaries, actigraphy, or 
polysomnography (29). Nonetheless, large-scale studies using more objective measures of 
sleep duration are needed, although they remain costly.
Second, our definition of an increase or decrease in sleep duration was conservative, 
resulting in few incident diabetes events in these categories. Larger studies with more finely 
graded data on sleep duration are required to address this limitation. Thirdly our study did 
not include measures of chronotype, sleep quality and sleep disorders, such as sleep apnea. 
There is some evidence that evening chronotype is associated with risk of type 2 diabetes 
(30), and disturbances in sleep quality are associated with impaired glucose regulation (27). 
Sleep apnea is highly prevalent in people with type 2 diabetes (31). Control for body mass 
index, as in the present study, may partially attenuate these associations but further research 
should include measures of sleep quality and sleep disorders, in particular sleep apnea. 
Lastly, findings from an occupational cohort of middle-aged, white-collar civil servants may 
not be generalizable, so should be confirmed in further prospective studies based on the 
general population. However, despite marked differences in both risk factors and disease 
incidence that favor the Whitehall II study, standard risk factor-cardiovascular disease 
associations are in close agreement with those observed in a UK-wide general population 
study (British Regional Heart Study) and the community-based Framingham study (32).
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